Infectious Disease Therapeutics Market

Global Infectious Disease Therapeutics Market Size, Trends & Analysis - Forecasts to 2026 By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Mode of Treatment (Drugs, Vaccines), By Drug Class (Anti-Bacterial, Anti-Viral, Anti-Parasite, Anti-Fungal, Others), By End-User (Hospital Pharmacy, Retail Pharmacy, Others), By Region (North America, Europe, Asia Pacific, Central & South America, Middle East & Africa); Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on April 30 2024 with the latest and most recent market numbers

Infectious Disease Therapeutics Market Insights

The global infectious disease therapeutics market is expected to grow from USD 48.77 billion in 2021 to USD 57.21 billion in 2026, at a CAGR of 7.12%.

The market drivers which contribute to the infectious disease therapeutics market growth include rising infectious disease, an increasing number of surgeries, high prevalence of chronic diseases such as cardiovascular and cancer, rising cases of accidents, changing food habits, lack of proper sanitation measures taken by healthcare providers, and personal unhygienic conditions, lack of antibodies & immunity, and growing patient pool.

On the other hand, the rising geriatric population, decrease in antibodies and immunity, growing adoption of anti-bacterial and other treatments are driving the growth of the market.

Moreover, the increasing technological advancements in infectious disease treatment, rising demand for novel therapeutics, and increasing research and development to launch advanced medical devices will help the market propel during the forecast period.

global infectious diseases therapeutics market

Infectious Disease Therapeutics Market: Disease Type

Based on disease type, the market is segmented into HIV infection, influenza, malaria, tuberculosis, hepatitis, and HPV infection. During the forecast period, the HIV infection segment will be growing fastest mainly due to the increasing incidence of HIV. HIV leads to low immunity, and increases the risk of bacterial infections.

During the forecast period, the hepatitis segment will be the second-largest segment due to increasing infections, lack of herd immunity, and new product launches. From 2021 to 2026, the market for HPV infection segment will be growing the fastest due to increasing STDs, lack of proper knowledge, increasing viral infections, rising government funding, and increasing R&D activities.

Infectious Disease Therapeutics Market: By Mode of Treatment

Based on the mode of treatment, the market is segmented into drugs and vaccines. During the forecast period, the drugs segment accounted for the largest market share in terms of value. Increasing demand for generic drugs, rising infectious diseases, growing chronic diseases, advanced technology, rising adoption of the latest treatment technology, are a few of the drivers that support the segment growth. Moreover, rising awareness about drugs and infectious disease, growing expenditure on healthcare facilities, rising geriatric population, and growing R&D activities are some of the other major factors that are driving this segment.

From 2021 to 2026, the vaccine segment will be growing fastest. Rising demand for immunization, increasing infectious diseases, growing government initiatives for vaccine production, investments from key players, increasing new pipeline product launches, growing R&D funding, the presence of a large patient population are major factors that are driving this segment.

Infectious Disease Therapeutics Market: By Drug Class

Based on drug class, the market is segmented into anti-bacterial, anti-viral, anti-parasite, and anti-fungal, among others. During the forecast period, the anti-bacterial segment is expected to hold the largest market share due to the increasing prevalence of infections like HIV, UTIs, and TB, Hepatitis A, and C. The government is taking initiatives to facilitate better treatment procedures and eradicate the presence of infectious diseases and chronic disorders. Changing food habits, lack of proper sanitation measures, decrease in antibodies and immunity, lack of awareness regarding personal hygiene, are increasing prevalence of infectious diseases are some of the factors driving the market growth.

Infectious Disease Therapeutics Market: By End-User

Based on end-user, the market is segmented into hospital pharmacy, and retail pharmacy, among others. During the forecast period, the hospital pharmacy segment is estimated to grow at the highest CAGR and also holds the largest market share due to the rising infectious parasitic diseases, increasing autoimmune disorders and inflammatory diseases, uprising problems in the gene, the requirement for early diagnosis, increasing research & development, and funding from the government. Also, the availability of advanced equipment and technology in hospital environments is the driving factor. The presence of trained and skilled healthcare professionals will boost hospitals even more. The market will expand due to an increase in healthcare spending, enhanced health consciousness, and increased health awareness. In developed countries, healthcare and diagnostic facilities are in higher demand.

asia pacific infectious diseases therapeutics market

Infectious Disease Therapeutics Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central South America.

During the forecast period, North America accounts for the largest market share mainly due to the presence of sophisticated healthcare facilities, rising inflammatory diseases, increasing autoimmune disorders, growing inflammatory diseases, the incidence of cancer and other chronic diseases and infections. Furthermore, the growing awareness among people, genetic disabilities, increasing skin disorders coupled with growing demand for treatment for skin disorders are driving this region growth.

Owing to the growing impact of chronic diseases and viral infections, rising inflammatory diseases, increasing autoimmune disorders, rising expenditure on healthcare facilities and altering inclination for advanced therapy, and booming investments in R&D activities are some of the leading factors driving the market growth. Moreover, the increasing accidents, genetic disease, increasing unhealthy diet habits, changing lifestyles, rising prevalence of climatic changes, are the major drivers due to which the Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period.

Infectious Disease Therapeutics Market Share and Competitor Analysis

F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Novartis AG, AbbVie, Inc., Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cubist, Eli Lilly and Company, and Sanofi, among others, are the major players in the market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global Infectious Disease Therapeutics Market Overview, 2020-2026

2.1.1 Industry Overview

2.1.2 Disease type Overview

2.1.3 Mode of Treatment Overview

2.1.4 Drug Class Overview

2.1.5 End-User Overview

2.1.6 Regional Overview

Chapter 3 Global Infectious Disease Therapeutics Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2020-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Increasing prevalence of infectious diseases

3.3.1.2 Growing awareness activities by non-profit organizations

3.3.2 Industry Challenges

3.3.2.1 Lack of reimbursement in selected countries

3.4 Prospective Growth Scenario

3.4.1 Disease type Growth Scenario

3.4.2 Mode of Treatment Growth Scenario

3.4.3 Drug Class Growth Scenario

3.4.4 End-User Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.7 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Global Infectious Disease Therapeutics Market, By Disease type

4.1 Disease type Outlook

4.2 HIV infection

4.2.1 Market Size, By Region, 2020-2026 (USD Billion)

4.3 Influenza